Galecto
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $281.9Mattributed |
|---|---|
| Latest round | seed, $259.2M, 2025-06-01attributed |
| Founded | 2011 |
| Headquarters | Copenhagen, Denmark |
| Industry | biotech |
| Stage | unknown |
| Website | galecto.com |
Damora Therapeutics (formerly Galecto) develops DMR-001, a subcutaneous monoclonal antibody targeting mutant calreticulin that drives essential thrombocythemia and myelofibrosis. It treats 42,000 US patients with mutCALR-driven MPNs. DMR-001 shows 10x potency versus reference antibodies and a 5x half-life extension.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | seed | $259.2M | undisclosed |
Detected tech stack
Cloudflare, Netlify, Typekit, Adobe Fonts, Next.js, React, Webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $259.2M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $281.9M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | galecto.com, read 2026-05-02 |
| Description | self-reported | galecto.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.